- Policy
- The MOHW’s new budget focuses on new drugs·COVID-19 trial
- by Lee, Jeong-Hwan Sep 10, 2020 06:23am
- While the budget plan of the MOHW for 2021 was released, it was found that the new budget focused on the treatment field, such as the national new drug development project and non-clinical support for COVID-19 treatment and vaccine. The new budget for the national new drug development project was ￦150.5 billion, and the new budget for non
- Policy
- MFDS to shorten fast-track review by a month
- by Lee, Tak-Sun Sep 10, 2020 06:23am
- With the latest reorganization effective from Aug. 31, South Korea’s Ministry of Food and Drug Safety (MFDS) has formed ‘Fast-track Review Division’ and ‘Preliminary Consulting Division’ under National Institute of Food and Drug Safety Evaluation (NIFDS) to expedite the review process on innovative new drugs. The pharmaceutical indu
- Company
- Pfizer pays ￦12 million to Upjohn‘s employees
- by Sep 10, 2020 06:23am
- Pfizer Pharmaceuticals Korea decided to pay ￦12 million in consolation to the employees of Upjohn who were transferred to Viatris, which was created as a merger with Mylan. According to the pharmaceutical industry on the 8th, Pfizer Pharmaceutical Korea has concluded negotiations with the union on consolation payments following the divis
- Company
- KDDF invests KRW 263 bln for 9 years but goal unachieved
- by Chon, Seung-Hyun Sep 9, 2020 05:52am
- The three government ministries’ first project to provide all-around support on new drug development, the Korea Drug Development Fund (KDDF) has ended its nine-year program. Although the goal of ‘developing 10 global new drugs’ was unachieved and the initially planned budget fell short, the project resulted in 50 license-out deals and it
- Policy
- Kang Do-tae & Jeong Eun-Kyeong were promoted
- by Kim, Jung-Ju Sep 9, 2020 05:49am
- Kang Do-tae, the current head of the Planning and Coordination Office (51, Seoul National University, Master of Public Administration), was appointed as the first multiple vice minister to lead the health sector of the Ministry of Health and Welfare. The next Vice Minister, Kang Do-tae, the first multiple Vice Minister of the MOHW, is in c
- Company
- Botulinum share in domestic market is 93%
- by Chon, Seung-Hyun Sep 9, 2020 05:47am
- Among domestically produced and imported botulinum toxin preparations, products developed by Korean companies accounted for more than 90%. Following Medytox, Hugel, and Daewoong Pharmaceutical, Huons Global and Pharma Research joined. The three types of Meditoxin, whose license was decided to be canceled, recorded ￦82.2 billion in production la
- Company
- Jung-Jin Seo, COVID-19 tx will be applied within this year
- by An, Kyung-Jin Sep 9, 2020 05:46am
- Jung-Jin Seo, Chairman at Celltrion announced that he will apply for approval for emergency use of COVID-19 antibody treatment within this year. The strategy is to finish early phase I clinical trial of the COVID-19 antibody treatment, which started at the end of July, and start an integrated phase II and III clinical trial at the end o
- Product
- Halted fight between government vs. doctors damages both
- by Kang, Shin-Kook Sep 9, 2020 05:46am
- The Korean Medical Association (KMA) has decided to temporarily halt but revisit their discussion with the government and the ruling party on increasing the quota for medical school and establishing public medical school, until COVID-19 is contained. The junior doctors are most likely to return for their duty after the last discussion on Sept. 7
- Company
- The government is worried about the generic exclusivity
- by Kim, Jin-Gu Sep 8, 2020 06:12am
- The generic exclusivity system is about to change in the fifth year of its introduction. Until now, the industry has been criticized for 'free ride' over this system. The core of the system is the grant of monopoly rights, and the contradictory situation in which monopoly was impossible was repeated. The discrimination power was lowered
- Policy
- How Tenelia latecomers lost chances in preferential sales
- by Lee, Tak-Sun Sep 8, 2020 06:11am
- Although Kyungdong Pharmaceutical first received approval on antidiabetic Tenelia’s incrementally modified drug (IMD), the drug is apparently not eligible for the preferential sales right given to the generic market. Regardless of the preferential right, any Tanelia IMDs that successfully evaded the original’s salt base patent can be l
